Company bets that AI-assisted analysis and a leaner trial design can get PrimeC to patients years sooner than the usual approval path.
Most people diagnosed with ALS don’t live past three years. Most drugs aiming to treat it spend longer than that just getting through a single confirmatory trial. That mismatch is the entire problem NeuroSense Therapeutics is trying to solve.
Late last month, the Cambridge, Massachusetts-based biotech announced it’s scrapping the traditional single-trial approach for its lead ALS candidate, PrimeC, in favor of three shorter, narrower studies. Each is designed to answer one specific question instead of trying to prove everything at once inside a single, years-long trial [1].
“One of the hardest constraints in ALS is not scientific; it is that the standard development path takes longer than patients have,” said Alon Ben-Noon, NeuroSense’s co-founder and CEO. “We have asked a straightforward question: what is the shortest reasonable route from the data we already hold to a therapy people can actually receive? This plan is our answer. It is faster, it costs less and it produces a stronger package, pharmacology, comparative clinical context and a pivotal dataset, than the single-trial approach would have.”
PrimeC pairs two already-approved drugs, ciprofloxacin, an antibiotic and celecoxib, an anti-inflammatory, into a single extended-release formulation. The idea isn’t novel chemistry so much as novel packaging: combine two known drugs to hit several of ALS’s suspected drivers simultaneously – nervous-system inflammation, iron accumulation in neurons and RNA regulation gone haywire – rather than betting everything on one mechanism the way most single-molecule drugs do.
The first piece of the plan is almost entirely desk work. NeuroSense already has pharmacokinetic data showing that PrimeC’s specific formulation produces a different, synchronized absorption pattern than simply taking the two component drugs side by side.
Rather than run a new trial to prove that, the company is applying AI-based modeling to data it already collected, hunting for a sharper, more defensible read on how big that difference actually is and how consistently it shows up across patients. It’s less a discovery than an extraction, pulling a stronger claim out of a file the company already owns.
The second study is the riskier bet. NeuroSense plans to run PrimeC head-to-head against edaravone, an ALS drug already on the market. Most ALS trials compare a candidate against a placebo, which is the safer route; there’s nowhere to hide the results if a placebo comparison goes badly, but there’s also less to gain. A direct win against an established competitor would hand NeuroSense something no placebo trial can: proof PrimeC beats what doctors are already prescribing. That’s the kind of evidence insurers and physicians weigh when deciding what to cover and prescribe.
Piece three reshapes PARAGON, the Phase 3 trial NeuroSense already has FDA clearance to run. The redesigned version would be smaller, shorter, and enroll patients earlier in their disease course, when meaningful decline is easier to detect over a compressed timeline. NeuroSense says it intends to ask the FDA directly whether existing data could support full approval outright, or whether accelerated approval, with a confirmatory study required afterward, is the more realistic path.
There’s also a second front open in Canada. NeuroSense has finished the pre-submission process with Health Canada and is targeting a formal filing by December, a track that could put PrimeC in Canadian patients’ hands before the US process wraps up.
The bigger wager
Underneath the trial mechanics, NeuroSense is testing something broader: whether AI-assisted analysis of data a company already has, paired with a leaner trial architecture, can shrink the distance between “we have promising evidence” and “patients can access this,” without cutting corners on rigor to get there.
For neurodegenerative disease specifically, where biological aging and disease progression run on the same clock, that kind of speed isn’t a nice-to-have. It’s the line between a therapy reaching someone in time to preserve years of function and reaching them after those years are already gone.
None of it is locked in yet. The FDA hasn’t signed off on the redesigned pivotal trial, and a head-to-head study against an approved competitor carries real reputational downside if PrimeC comes up short. However, the underlying argument – that the industry’s default trial timeline is itself an obstacle to treating aging-related disease, however sound the science behind a drug turns out to be – is one more companies working in this space are likely to test in the next few years.
